A Phase 3 interventional study of rMenB+OMV NZ vaccine in Meningitis, sponsored by GlaxoSmithKline. Completed at 17 sites in 4 countries. Open to participants aged 10 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Meningitis by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningitis · GlaxoSmithKline.
Among the 16 studies in Meningitis by GlaxoSmithKline, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 10 in phase 3, and was the 16th registered.
268 studies on the registry are indexed under Meningitis; 28 are open to participants now.
Browse Meningitis studies →None of the 16 studies in Meningitis by GlaxoSmithKline is open now. The open studies under Meningitis, anywhere →
Of the 17 Meningitis studies recruiting now, 11 (65%) set no upper age limit and 6 (35%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 10 Years to 20 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
This study's enrollment of 312 is above the median of 260 across 185 interventional studies indexed under Meningitis.
Median enrollment 704 across the 15 interventional studies, 36,366 across the 1 observational. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Meningitis by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study was to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years. This study focused on individuals who were first vaccinated with rMenB+OMV NZ as infants. The primary hypothesis was that a booster dose of the vaccine would elicit a stronger immune response in these primed individuals compared to those who had never received any group B meningococcal vaccine, referred to as 'naïve' participants.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants were eligible to be included in the study only if all of the following criteria applied:
For primed group only:
OR
For naïve group only:
For all participants:
Note: For age 10-16 years, parents or LAR to give consent along with participants, based on country regulations for participants and for >16/18 to 20 years, participants give consent independent of parents/LARs, or as per local country regulations.
Female participants of childbearing potential may be enrolled in the study, if the participant:
Exclusion Criteria:
Participants were excluded from the study if any of the following criteria applied:
Medical conditions
Prior/Concomitant therapy
Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.
For primed group only:
Prior/Concurrent clinical study experience
Other exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were primed with rMenB+OMV NZ vaccine in a 3 (2+1) doses or 4 (3+1) doses vaccination schedule during the first 2 years of life, received 1 dose of rMenB+OMV NZ vaccine at Day 1.
Biological: rMenB+OMV NZ vaccine
Participants who never received any group B meningococcal vaccine previously, received 2 doses of rMenB+OMV NZ vaccine, one at Day 1 and one at Day 31.
Biological: rMenB+OMV NZ vaccine
Drug page: 4CMenB vaccine
1 dose in the Primed group or 2 doses in the Naïve group.
Also known as: Bexsero
Human Serum Bactericidal Assay (hSBA) Titers Expressed as Geometric Mean Titers (GMTs) Against Each MenB Indicator Strain, and Between-group GMT Ratios at Day 31
hSBA titers against each MenB indicator strain were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
Time frame: At Day 31
Percentage of Participants With hSBA Titers Greater Than or Equal (>=) to 4 Against Each MenB Indicator Strain at Day 31
The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
Time frame: At Day 31
Percentage of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Each MenB Indicator Strain at Day 31
The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
Time frame: At Day 31
Percentage of Participants With >=4-fold Increase in hSBA Titers Against Each MenB Indicator Strain at Day 31 Relative to Day 1
The percentage of participants with \>=4-fold increase in hSBA titers against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA. 4-fold increase in hSBA titers is defined as: * Post-vaccination hSBA titers \>= 8 for participants with pre-vaccination hSBA titers lower than (\<) 2; * Post-vaccination hSBA titers \>= 4 times the pre-vaccination hSBA titers for participants with pre-vaccination hSBA titers \>=2.
Time frame: At Day 31 relative to Day 1
hSBA Geometric Mean Ratios (GMRs) Against Each MenB Indicator Strain at Day 31 Compared to Baseline (Day 1)
The immune response to the rMenB+OMV NZ vaccine against each MenB indicator strain was evaluated in terms of hSBA GMRs and expressed as within-group ratios of hSBA GMTs against each of the MenB indicator strains at Day 31 compared to Baseline (Day 1). The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
Time frame: At Day 31 compared to Baseline (Day 1)
Percentage of Participants With hSBA Titers >=4 Against Each MenB Indicator Strain at Baseline (Day 1)
The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
Time frame: At Baseline (Day 1)
Percentage of Participants With hSBA Titers >=LLOQ Against Each Serogroup B Indicator Strain at Baseline (Day 1)
The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
Time frame: At Baseline (Day 1)
hSBA Titers Expressed as GMTs Against Each MenB Indicator Strain at Baseline (Day 1)
hSBA titers against each MenB indicator strains were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
Time frame: At Baseline (Day 1)
Number of Participants Reporting Any Solicited Administration Site Events
The assessed solicited administration site events included administration site erythema (redness), swelling, pain and induration. Any = occurrence of the event regardless of intensity grade.
Time frame: Within 7 days after the first vaccination occurring at Day 1
Number of Participants Reporting Any Solicited Systemic Events
The assessed solicited systemic events included headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness), nausea and fever (pyrexia). Fever is defined as body temperature \>=38.0°C/100.4°F. The preferred location for measuring temperature in this study was axillary. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Time frame: Within 7 days after the first vaccination occurring at Day 1
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of the intensity grade or relation to the study vaccination.
Time frame: Within 31 days after the first vaccination occurring at Day 1
Number of Participants Reporting an Adverse Event of Special Interest (AESI) (Arthritis)
AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. The assessed AESI in this study was arthritis.
Time frame: From Day 1 to Day 31
Number of Participants Reporting Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, in an abnormal pregnancy outcome, or in other situations that were considered serious per medical or scientific judgment.
Time frame: From Day 1 to Day 31
Number of Participants Reporting AEs Leading to Withdrawal
AEs leading to withdrawal are defined as AEs due to which the participant is considered to have withdrawn from the study as no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact.
Time frame: From Day 1 to Day 31
The study population consisted of eligible participants who were previously primed with rMenB+OMV NZ vaccine in studies V72\_28 (EudraCT number: 2010-021528-81), V72\_P12E1 (EudraCT number: 2009-011676-30), V72\_P13E1 (EudraCT number: 2008-006301-17) or in routine practice during the first 2 years of life, and of vaccine-naïve participants, who never received any group B meningococcal vaccine previously.
| Milestone | Primed Group | Naïve Group |
|---|---|---|
| Started | 234 | 78 |
| Completed | 233 | 78 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
hSBA titers against each MenB indicator strain were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
| Titers | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 24.2 (20.4 to 28.8) | 6.2 (4.7 to 8.2) |
| NadA | 844.9 (704.5 to 1013.3) | 54.3 (40.0 to 73.8) |
| NHBA | 14.0 (12.1 to 16.4) | 10.4 (8.1 to 13.3) |
| PorA | 10.0 (8.4 to 11.9) | 5.7 (4.2 to 7.6) |
The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
| Percentage of participants | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 87.9 (83.0 to 91.8) | 64.1 (52.4 to 74.7) |
| NadA | 99.1 (96.9 to 99.9) | 87.2 (77.7 to 93.7) |
| NHBA | 85.7 (80.4 to 89.9) | 56.6 (44.7 to 67.9) |
| PorA | 70.7 (64.4 to 76.5) | 41.6 (30.4 to 53.4) |
The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
| Percentage of participants | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 86.2 (81.1 to 90.4) | 56.4 (44.7 to 67.6) |
| NadA | 99.1 (96.9 to 99.9) | 71.8 (60.5 to 81.4) |
| NHBA | 81.3 (75.7 to 86.1) | 51.3 (39.6 to 63.0) |
| PorA | 62.1 (55.5 to 68.3) | 40.3 (29.2 to 52.1) |
The percentage of participants with \>=4-fold increase in hSBA titers against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA. 4-fold increase in hSBA titers is defined as: * Post-vaccination hSBA titers \>= 8 for participants with pre-vaccination hSBA titers lower than (\<) 2; * Post-vaccination hSBA titers \>= 4 times the pre-vaccination hSBA titers for participants with pre-vaccination hSBA titers \>=2.
| Percentage of participants | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 74.9 (68.8 to 80.3) | 28.6 (18.8 to 40.0) |
| NadA | 98.3 (95.6 to 99.5) | 68.8 (57.3 to 78.9) |
| NHBA | 54.9 (48.0 to 61.7) | 29.3 (19.4 to 41.0) |
| PorA | 51.5 (44.9 to 58.1) | 30.3 (20.2 to 41.9) |
The immune response to the rMenB+OMV NZ vaccine against each MenB indicator strain was evaluated in terms of hSBA GMRs and expressed as within-group ratios of hSBA GMTs against each of the MenB indicator strains at Day 31 compared to Baseline (Day 1). The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
| Ratio | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 9.69 (8.15 to 11.52) | 2.38 (1.79 to 3.16) |
| NadA | 90.19 (74.47 to 109.22) | 8.67 (6.34 to 11.87) |
| NHBA | 4.03 (3.43 to 4.74) | 2.82 (2.16 to 3.66) |
| PorA | 4.31 (3.61 to 5.14) | 2.43 (1.81 to 3.25) |
The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
| Percentage of participants | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 15.9 (11.4 to 21.2) | 16.9 (9.3 to 27.1) |
| NadA | 57.3 (50.7 to 63.7) | 23.4 (14.5 to 34.4) |
| NHBA | 27.4 (21.6 to 33.8) | 22.1 (13.4 to 33.0) |
| PorA | 7.7 (4.6 to 11.9) | 5.2 (1.4 to 12.8) |
The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
| Percentage of participants | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 11.6 (7.8 to 16.4) | 16.9 (9.3 to 27.1) |
| NadA | 43.6 (37.1 to 50.2) | 13.0 (6.4 to 22.6) |
| NHBA | 22.8 (17.4 to 29.0) | 20.8 (12.4 to 31.5) |
| PorA | 6.4 (3.6 to 10.4) | 5.2 (1.4 to 12.8) |
hSBA titers against each MenB indicator strains were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.
| Titers | Primed Group | Naïve Group |
|---|---|---|
| fHbp | 2.5 (2.3 to 2.7) | 2.8 (2.4 to 3.2) |
| NadA | 10.8 (9.2 to 12.6) | 4.3 (3.3 to 5.5) |
| NHBA | 3.4 (2.9 to 4.0) | 3.9 (3.0 to 5.0) |
| PorA | 2.3 (2.2 to 2.5) | 2.4 (2.1 to 2.7) |
The assessed solicited administration site events included administration site erythema (redness), swelling, pain and induration. Any = occurrence of the event regardless of intensity grade.
| Participants | Primed Group | Naïve Group |
|---|---|---|
| Erythema (Redness) | 34 | 9 |
| Swelling | 44 | 12 |
| Pain | 230 | 77 |
| Induration | 44 | 10 |
The assessed solicited systemic events included headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness), nausea and fever (pyrexia). Fever is defined as body temperature \>=38.0°C/100.4°F. The preferred location for measuring temperature in this study was axillary. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
| Participants | Primed Group | Naïve Group |
|---|---|---|
| Headache | 128 | 39 |
| Myalgia (Muscle pain) | 164 | 56 |
| Arthralgia (Joint pain) | 79 | 30 |
| Fatigue (Tiredness) | 180 | 58 |
| Nausea | 49 | 17 |
| Fever (Pyrexia) | 6 | 1 |
An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of the intensity grade or relation to the study vaccination.
| Participants | Primed Group | Naïve Group |
|---|---|---|
| Number of Participants Reporting Any Unsolicited Adverse Events (AEs) | 49 | 11 |
AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. The assessed AESI in this study was arthritis.
| Participants | Primed Group | Naïve Group |
|---|---|---|
| Number of Participants Reporting an Adverse Event of Special Interest (AESI) (Arthritis) | 0 | 0 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, in an abnormal pregnancy outcome, or in other situations that were considered serious per medical or scientific judgment.
| Participants | Primed Group | Naïve Group |
|---|---|---|
| Number of Participants Reporting Serious Adverse Events (SAEs) | 1 | 0 |
AEs leading to withdrawal are defined as AEs due to which the participant is considered to have withdrawn from the study as no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact.
| Participants | Primed Group | Naïve Group |
|---|---|---|
| Number of Participants Reporting AEs Leading to Withdrawal | 0 | 0 |
Collected over Solicited AEs: within 7 days after the first vaccination. Unsolicited AEs: within 31 days after the first vaccination. All-cause mortality, all SAEs, AEs leading to withdrawal, AESI (arthritis): from Day 1 to Day 31.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primed Group | 0/234 (0%) | 1/234 (0.4%) | 233/234 (99.6%) |
| Naïve Group | 0/78 (0%) | 0/78 (0%) | 77/78 (98.7%) |
| Event | Primed Group | Naïve Group |
|---|---|---|
| AppendicitisInfections and infestations | 1/234 | 0/78 |
| Event | Primed Group | Naïve Group |
|---|---|---|
| Administration site painGeneral disorders | 230/234 | 77/78 |
| FatigueGeneral disorders | 180/234 | 58/78 |
| MyalgiaMusculoskeletal and connective tissue disorders | 164/234 | 56/78 |
| HeadacheNervous system disorders | 129/234 | 39/78 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 79/234 | 30/78 |
| NauseaGastrointestinal disorders | 49/234 | 17/78 |
| Administration site indurationGeneral disorders | 44/234 | 10/78 |
| Administration site swellingGeneral disorders | 44/234 | 12/78 |
| Administration site rednessGeneral disorders | 34/234 | 9/78 |
| PyrexiaGeneral disorders | 8/234 | 1/78 |
| Age, Continuous(Years) | Primed Group | Naïve Group | Total |
|---|---|---|---|
| Mean | 15.3 ± 2.2 | 14.8 ± 2.6 | 15.2 ± 2.3 |
| Sex: Female, Male(Participants) | Primed Group | Naïve Group | Total |
|---|---|---|---|
| Female | 126 | 44 | 170 |
| Male | 108 | 34 | 142 |
| Race/Ethnicity, Customized(Participants) | Primed Group | Naïve Group | Total |
|---|---|---|---|
| Black or African American | 0 | 1 | 1 |
| Multiple | 1 | 2 | 3 |
| Not reported | 1 | 0 | 1 |
| White | 232 | 75 | 307 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
Results were first posted in Nov 2026, 10 months after primary completion.
Of 19 phase 3 interventional studies under Meningitis, half reached primary completion within 15 months of starting (the median); a quarter within 7 and three quarters within 28. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine